Fibroblast growth factor 10 haploinsufficiency causes chronic obstructive pulmonary disease

Joakim Klar,1 Peter Blomstrand,2 Charlott Brunmark,3 Jitendra Badhai,1 Hanna Falk Håkansson,3 Charlotte Sollie Brange,3 Birgitta Bergendal,4 Niklas Dahl1

ABSTRACT
Background Genetic factors influencing lung function may predispose to chronic obstructive pulmonary disease (COPD). The fibroblast growth factor 10 (FGF10) signalling pathway is critical for lung development and lung epithelial renewal. The hypothesis behind this study was that constitutive FGF10 insufficiency may lead to pulmonary disorder. Therefore investigation of the pulmonary functions of patients heterozygous for loss of function mutations in the FGF10 gene was performed.

Methods The spirometric measures of lung function from patients and non-carrier siblings were compared and both groups were related to matched reference data for normal human lung function.

Results The patients show a significant decrease in lung function parameters when compared to control values. The average FEV1/FVC quota (FEV1%) for the patients is 0.65 (80% of predicted) and reversibility test using Terbutalin resulted in a 3.7% increase in FEV1. Patients with FGF10 haploinsufficiency have lung function parameters indicating COPD. A modest response to Terbutalin confirms an irreversible obstructive lung disease.

Conclusion These findings support the idea that genetic variants affecting the FGF10 signalling pathway are important determinants of lung function that may ultimately contribute to COPD. Specifically, the results show that FGF10 haploinsufficiency affects lung function measures providing a model for a dosage sensitive effect of FGF10 in the development of COPD.

INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a complex disease and one of the leading causes of death in developed countries. The disease results from major remodelling of the airspace and changes in the lung epithelium.1 The simplest classification of COPD is related to the degree of airflow obstruction, regardless of the underlying mechanism. In contrast to asthma, which is defined by a reversible airflow obstruction, COPD is characterised by irreversible and usually progressive obstruction with an abnormal inflammatory response to noxious gases or particles.2 3 The most important risk factor for the development of COPD is cigarette smoking, but only a minority of smokers will develop the disease, suggesting contributions of genetic factors.4 This is supported by the demonstration of familial aggregation of lung function measures as well as the clustering of COPD within families.5 Genetic studies in humans and in animal models suggest that genes associated with lung developmental processes are also implicated in COPD.1 4 6 Lung development requires branching morphogenesis, a process that is dependent on cell–cell communication between the mesenchyme and the lung epithelium. Both lung development and lung homeostasis depend on precise molecular signalling involving different fibroblast growth factors (FGF), sonic hedgehog (SHH), bone morphogenetic protein (BMP), transforming growth factor β (TGFβ), retinoic acid, the wingless (WNT) related family of proteins, and various transcription factors.7 8 Similar mechanisms are required to maintain and regenerate the lung epithelium from progenitor cells located both in the epithelium and in the mesenchyme along the airways.9 Thus, factors and molecular pathways involved in the differentiation and renewal of the lung epithelium provide candidate mechanisms in pulmonary disease.10 11

FGF10 is expressed in the mesenchyme and its signalling is mediated by the receptor FGFR2b required for the development of many branched organs including lungs, thyroid, pituitary, lacrimal, and salivary glands.12 13 During early lung development, FGF10 signalling is tightly regulated by the retinoic acid dependent network through either WNT (via DKK1) or TGFβ-1 signalling.8 In the developing lung FGF10 is regulated by SHH signalling and other members of the FGF family.13 16 Furthermore, decreased FGF10-FGFR2 signalling alters the expression of SHH and BMP4, as well as FGF10 itself, establishing a feedback loop.17 The importance of the FGF10 pathway during lung initiation and development has been established in model systems after targeted disruption of the corresponding genes or by ectopic over-expression of the proteins.18 20 The most profound disruption of lung morphogenesis is observed in Fgf10 and Fgfr2 null mice embryos showing failure to form lung buds.21 24 In the adult lung, FGF10 has been identified as a survival factor, and exogenous Fgf10 expression in mice decreases induced alveolar epithelial cell DNA damage, apoptosis, and the extent of induced lung fibrosis.25 26 Furthermore, FGF10 is coordinately expressed with BMP4 during hyperoxia injury repair.27 In vitro studies have recently shown that soluble FGF10 and hepatocyte growth factor (HGF) can replace the requirement for mesenchymal support in lung epithelial formation, allowing for clonal expansion and self-renewal.5 These data support a model in which the adult lung contains FGF10 dependent cells, giving rise to airway and alveolar epithelial cell lineages.
In humans, heterozygous mutations in the genes encoding FGF10 or FGF2b result in autosomal dominant aplasia of lacrimal and salivary glands (ALSG) and lacrimo-auriculo-dento-digital syndrome (LADD), respectively. No lung phenotype has been described in these patients, with the exception of a male LADD patient presenting with complex pulmonary malformations.28–32 FGF10 and FGF2b are essential for lung initiation, lung development, and lung epithelial proliferation in experimental systems, and we hypothesised that haploinsufficiency for FGF10 affects lung function that may ultimately result in the development of COPD.33 To examine this hypothesis, we measured the pulmonary functions in patients with loss of function mutations in the FGF10 gene as well as their non-carrier siblings. Spirometric values from both groups were compared with reference data for pulmonary functions.34 Lung function parameters were also measured in a mice model heterozygous for Fgf10 in order to validate a pulmonary phenotype. Our results indicate that FGF10 haploinsufficiency affects lung function that may ultimately lead to the development of COPD.

METHODS

Patients

Twelve patients with ALSG and heterozygous loss of function mutations in FGF10 were included in this study. The patients belong to two previously described families segregating a deletion (n=10) or a nonsense mutation (n=2) in the FGF10 gene, respectively.29 The age range of patients was from 13–69 years, with a mean age of 39 years. Six patients were male and six female. Six of the 12 patients were diagnosed with ‘asthma’ before this study and four patients had milder allergies. Two were smokers (<one package a day), three patients stopped smoking 3–11 years ago, and seven patients never smoked (supplementary table S1). None of the patients had any known lung malformation or abnormal tendency for airway/lung infections. Three non-carrier siblings (age 30, 33 and 34 years, one male and two females, respectively) from one family were included as ‘internal’ controls. Informed consent was obtained from all adult participants or parents of children who participated in this study under a protocol approved by the Regional Ethical Committee.

Mice

Mice heterozygous for the Fgf10 gene22 were housed and bred in the animal core facility of the Biomedical Centre, Uppsala University under pathogen-free conditions. In total, 12 haploinsufficient (Fgf10 +/-) mice and 12 wt (Fgf10 +/+ ) mice (C57BL/6) were used in this study at 13–17 weeks of age. Genotyping was performed using a primer against the neo-cassette together with a specific mouse Fgf10 primer (available upon request). The study followed a protocol approved by the Regional Ethical Committee for animal experiments.

Pulmonary function

Lung function measurements of study participants were performed by trained technicians and according to the American Thoracic Society (ATS) or European Respiratory Society (ERS) criteria.35 Lung function in mice was investigated using the eSpira Forced Manoeuvres System (FMS) (EMMS, Hants, UK). Human: We measured forced expiratory volume during 1 s (FEV1) and vital capacity (VC) using a computerised pneumotachograph spirometer. Inspiratory vital capacity (IVC) was measured and total lung capacity (TLC) calculated with a volume plethysmograph (Jaeger Masterscreen body; Hoechberg, Germany). FEV1 was determined after treatment with terbutaline. Mouse: Mice were anaesthetised (0.2 ml/20 g mouse, intraperitoneally, with ketamine, xylazine, acepromazine, and saline, 2:1:0.3:6 ml). The eSpira FMS was used to assess the lung function parameters forced expiratory volume in 75 ms (FEV75), forced vital capacity (FVC), inspiratory capacity, and TLC.

RESULTS

Lung function in human subjects

The FGF10 heterozygous patients showed a significant decrease in IVC (83% of predicted; p<0.001), FEV1 (68% of predicted; p<0.001), and FEV1/IVC quota (FEV1% 0.65; p<0.001), but not in TLC (95% of predicted; p=0.12) (table 1 and table S2).
Table 1  Spirometric characteristics of FGF10 heterozygous individuals and three non-carrier siblings with predicted reference values

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Patients (n = 12)</th>
<th>Predicted (LLN)</th>
<th>% of predicted</th>
<th>Paired t test</th>
<th>Controls (n = 3)</th>
<th>Predicted (LLN)</th>
<th>% of predicted</th>
<th>Paired t test</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV1</td>
<td>3.94±0.97</td>
<td>4.50 (3.60)</td>
<td>82%±14</td>
<td>0.0038*</td>
<td>4.56±0.74</td>
<td>4.69 (3.86)</td>
<td>99%±9</td>
<td>0.71</td>
</tr>
<tr>
<td>FEV1/IVC</td>
<td>2.56±0.70</td>
<td>3.63 (2.87)</td>
<td>68%±11</td>
<td>7.88×10⁻⁶*</td>
<td>3.76±0.74</td>
<td>3.85 (3.76)</td>
<td>98%±4</td>
<td>0.41</td>
</tr>
<tr>
<td>FEV1/IFVC</td>
<td>0.65±0.06</td>
<td>0.82 (0.71)</td>
<td>85%±7</td>
<td>1.86×10⁻⁴**</td>
<td>0.82±0.06</td>
<td>0.83 (0.82)</td>
<td>99%±9</td>
<td>0.84</td>
</tr>
<tr>
<td>TLC</td>
<td>6.01±1.43</td>
<td>6.45 (5.39)</td>
<td>93%±14</td>
<td>0.12</td>
<td>6.36±1.47</td>
<td>6.19 (5.19)</td>
<td>103%±5</td>
<td>0.42</td>
</tr>
</tbody>
</table>

*Denote significant difference of p<0.05 using two-tailed paired t test.
BMI, body mass index; IVC, inspiratory vital capacity; FEV1, forced expiratory volume in 1 s; TLC, total lung capacity.

Significant differences in FEV1 and FEV1/IVC were also observed when comparing FGF10 heterozygous patients and the three non-carrier siblings used as controls (table 2). The values of the non-carrier siblings were similar to their predicted values, validating them as ‘internal’ controls in the study (table 1). Consistent with pulmonary obstructive disease, the average FEV1/IVC was reduced (<0.7 and <LLN) and the FEV1 (<80% of predicted) and a normal, or slightly reduced IVC (IVC >80% of predicted; table 1). Reversibility test using terbutaline gave a significant increase in FEV1 (3.7% of predicted value, p<0.0013; table 2). This was still subnormal when compared to the predicted reference value (2.70±0.75 vs 3.63±0.60 (LLN 2.37±0.50); tables 1 and 2). Smoking, or having a history of smoking, did not correlate with lower IVC, FEV1 or FEV1/IVC in our group of patients (supplementary tables S1 and 2). Individual data revealed two individuals (MS90 and GA80) classified as COPD according to the GOLD standard, but they could be defined as false negatives when applying the ATS/ERS 2005 standard (supplementary table S2). On the other hand, the two oldest individuals (IA97 and BA45) were classified as COPD according to the GOLD standard but could be considered as false positive using the ATS/ERS 2005 standard. Individual BA45 was ‘borderline’ normal with an FEV1/IVC of 0.65 (LLN 0.64), while individual IA97 could be classified as having a restrictive phenotype with a normal FEV1/IVC (0.66 > LLN 0.62), due to a very low IVC (2.86 < LLN 3.46), and a low TLC (6.05 < LLN 6.11). Individual LA41 had an obstructive disease (FEV1/IVC 0.627 < LLN 0.632) with restrictive components (IVC 3.35 < LLN 3.71, and TLC 5.11 < LLN 6.27), indicating a mixed phenotype.

Lung function in mouse model

Fgf10+/− mice showed a significant decrease in FEV75%, FVC, as well as a decrease in the FEV75%/FVC quota (FEV75%). The mice also had a decreased lung size (TLC) as well as body and lung weight compared to wild type (wt) male littersmates. However, the lung/body weight ratio was similar when comparing Fgf10+/− and Fgf10+/+ mice. To eliminate a possible effect of body and lung size, mice data were normalised to lung capacity, body weight, lung weight, and by comparing weight matched mice. When comparing weight matched Fgf10+/− and Fgf10+/+ mice we observed a slight decrease in lung weight (supplementary table S3). Lung morphology and histopathology (giemsa staining) appeared normal in Fgf10+/− mice (supplementary figure 1).

DISCUSSION

Independent genome-wide association studies (GWAS) have recently identified single nucleotide polymorphisms (SNPs) near the hedgehog interacting protein (HHIP) locus on chromosome 4 associated with airflow obstruction.43–46 HHIP is a critical negative regulator of the hedgehog pathway, including the ligand sonic hedgehog (SHH). Overexpression of SHh in mouse lung rudiments reduces transcription of the Fgf10 gene.12 Similarly to mice deficient for Fgf10, branching morphogenesis is greatly impaired in mice deficient for Hhip and it has been hypothesised that the lung phenotype in Hhip deficient mice results from hyperactive SHh followed by inhibition of Fgf10 expression.17 This may explain the morphological similarities in mouse models deficient for either Hhip or Fgf10 and supports altered Fgf10 expression as a candidate mechanism in COPD.20 Interestingly, the Fgf10 downstream target, STAT V3, has recently been associated with COPD, providing yet another link to Fgf10 signalling.27

The results of our study show that haploinsufficiency for Fgf10 is associated with reduced pulmonary function consistent with COPD.2 FGF10 insufficient patients show a non-reversible airway obstruction when compared with both predicted reference values and siblings with normal FGF10 expression.

Table 2  Physical and spirometric characteristics of FGF10 heterozygous individuals and non-carrier siblings

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Patients (n = 12)</th>
<th>Paired t test†</th>
<th>Controls (n = 3)</th>
<th>Paired t test†</th>
<th>Student t test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>39±21</td>
<td></td>
<td>32±2</td>
<td></td>
<td>0.623</td>
</tr>
<tr>
<td>Length (cm)</td>
<td>174.2±8.6</td>
<td></td>
<td>172.7±11.2</td>
<td></td>
<td>0.802</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>73.8±18.7</td>
<td></td>
<td>72.0±1.7</td>
<td></td>
<td>0.871</td>
</tr>
<tr>
<td>BMI</td>
<td>24.1±4.4</td>
<td></td>
<td>24.3±3.6</td>
<td></td>
<td>0.903</td>
</tr>
<tr>
<td>IVC</td>
<td>3.94±0.97</td>
<td></td>
<td>4.56±0.74</td>
<td></td>
<td>0.320</td>
</tr>
<tr>
<td>FEV1</td>
<td>2.56±0.70</td>
<td></td>
<td>3.76±0.74</td>
<td></td>
<td>0.020*</td>
</tr>
<tr>
<td>FEV1/IFVC</td>
<td>0.65±0.06</td>
<td></td>
<td>0.82±0.06</td>
<td></td>
<td>1.86×10⁻⁴**</td>
</tr>
<tr>
<td>TLC</td>
<td>6.01±1.43</td>
<td></td>
<td>6.36±1.47</td>
<td></td>
<td>0.714</td>
</tr>
<tr>
<td>FEV1 after terbutaline</td>
<td>2.70±0.73</td>
<td>0.0013*</td>
<td>3.95±0.86</td>
<td>0.057</td>
<td>0.019*</td>
</tr>
<tr>
<td>IVC after terbutaline</td>
<td>3.88±0.95</td>
<td>0.51</td>
<td>4.79±0.73</td>
<td>0.035</td>
<td>0.146</td>
</tr>
</tbody>
</table>

*Denote significant difference of p<0.05 using †two tailed paired t test before and after terbutaline treatment and two-tailed paired t test between observed and predicted values.
†Plus—minus values are means±SD.
BMI, body mass index; IVC, inspiratory vital capacity; FEV1, forced expiratory volume in 1 s; FEV1/IFVC, FEV1%; TLC, total lung capacity.
alleles. These findings provide a direct connection between FGF10 expression and human lung function. Patients with FGF10 insufficiency, also associated with the ALSG syndrome, have a significantly reduced FEV1 (68% of predicted) and an average FEV1/IVC of 0.65 (normally above 0.70–0.75) consistent with obstructive lung disease. This is supported by a normal TLC and a disproportionately and slightly reduced IVC (83% of predicted). In COPD, both FEV1 and IVC are below predicted levels, but the FEV1/IVC ratio is normal or increased. The modest increase in FEV1 (5.7% of predicted value) after terbutaline treatment in our patients indicates that the obstructive symptoms are irreversible. A reversible obstruction (eg, asthma) is defined by an increase of at least 12% in FEV1 in response to terbutaline treatment. The degree of COPD in our group of patients is classified as moderate or stage II COPD (FEV1/IVC < LLN and 60% <FEV1 <69% of predicted).41

To validate our results from spirometric measures in patients with FGF10 haploinsufficiency we studied the pulmonary functions in Fgf10 heterozygous mice. Even though FGF10 deficient mice show a reduction in pulmonary functions similar to those observed in our patients, these results are most probably due to the smaller size of the Fgf10 +/− mice. Studies of pulmonary functions in mice indicate that direct comparisons between mice and human for key variables such as FEV and FVC are less useful.50 The mouse lung shares general structure and physiological mechanisms with the human lung but with some differences. Mice have fewer submucosal glands restricted to the terminal bronchiole.51 Furthermore, the respiratory bronchioli—structures shown to be involved in the development of emphysema—are absent in the mouse.52 These differences may, in part, explain the differences in spirometric measurements between mice and man.

Despite tremendous efforts to understand the genetics behind COPD, most factors remain obscure with rare exceptions such as α1-antitrypsin deficiency.20 43–47 53–56 Our results support the idea that genetic variants affecting the FGF10 signalling pathway are important determinants of lung function that may ultimately contribute to COPD. Specifically, we show that FGF10 haploinsufficiency affects lung function measures, providing a model for a dosage sensitive effect of FGF10 in the development of COPD.

Acknowledgements We thank all participants who participated in this study. We are also indebted to Rebecca Lewis for performing the spirometric analyses. Mice heterozygous for the Fgf10 gene were generously shared by Dr H. Ohuchi, University of Tokushima, Japan.

Funding This work was supported by the Swedish Research Council, Uppsala University, Uppsala University Hospital, the Swedish Society for Medical Research, and Futurum academy of science and healthcare, Jönköping County Council.

Competing interests None.

Ethics approval The human studies were approved by the local ethics committee in Jönköping, Sweden, and with the informed consent of the patients. The animal studies were approved by the local ethics committee in Uppsala, Sweden, and performed according to governmental guidelines.

Contributors JK wrote the manuscript, performed statistical analyses and interpreted the data. CB, JB, HHH, and CSB performed the experiments. PB and BB participated in study design and data interpretation. ND designed the study and edited the manuscript.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


Fibroblast growth factor 10 haploinsufficiency causes chronic obstructive pulmonary disease

Joakim Klar, Peter Blomstrand, Charlott Brunmark, Jitendra Badhai, Hanna Falk Håkansson, Charlotte Sollie Brange, Birgitta Bergendal and Niklas Dahl

*J Med Genet* 2011 48: 705-709 originally published online July 8, 2011
doi: 10.1136/jmedgenet-2011-100166

Updated information and services can be found at:
http://jmg.bmj.com/content/48/10/705

Supplementary material can be found at:
http://jmg.bmj.com/content/suppl/2011/07/08/jmedgenet-2011-100166.DC1

This article cites 56 articles, 18 of which you can access for free at:
http://jmg.bmj.com/content/48/10/705#BIBL

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Articles on similar topics can be found in the following collections

- Editor's choice (119)
- Genetic screening / counselling (886)
- Drugs: endocrine system (106)
- Reproductive medicine (518)

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/